4114 Income Statement - TTM - Synmosa Biopharma Corporation

Income Statement (TTM)

Synmosa Biopharma Corporation Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	2,931	3,038	3,012	3,105	3,141	3,235	3,441	3,721	4,048	4,386	4,677	4,931	5,059	5,140	5,164	5,186	5,375	5,550	5,716	5,995
Change (%)		3.67	-0.85	3.06	1.18	2.98	6.38	8.12	8.80	8.35	6.64	5.42	2.61	1.60	0.46	0.42	3.65	3.24	2.99	4.90
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	1,868	1,905	1,861	1,895	1,906	1,950	2,048	2,184	2,385	2,560	2,745	2,896	2,953	3,021	2,987	2,983	3,068	3,149	3,244	3,377
Change (%)		1.99	-2.35	1.87	0.59	2.26	5.05	6.63	9.20	7.33	7.22	5.52	1.95	2.30	-1.11	-0.14	2.84	2.64	3.02	4.10
% of Revenue	63.74	62.71	61.76	61.05	60.69	60.27	59.51	58.69	58.91	58.36	58.68	58.74	58.36	58.76	57.84	57.52	57.07	56.74	56.75	56.32

Gross Operating Profit	1,063	1,133	1,152	1,209	1,235	1,285	1,393	1,537	1,664	1,827	1,933	2,035	2,107	2,120	2,177	2,203	2,308	2,401	2,472	2,619
Change (%)		6.62	1.66	4.98	2.12	4.10	8.39	10.33	8.24	9.80	5.81	5.26	3.55	0.62	2.70	1.18	4.75	4.05	2.96	5.95
% of Revenue	36.26	37.29	38.24	38.95	39.31	39.73	40.49	41.31	41.09	41.64	41.32	41.26	41.64	41.24	42.16	42.48	42.93	43.26	43.25	43.68

SG&A	800	826	837	844	857	884	923	982	1,078	1,151	1,229	1,278	1,282	1,292	1,298	1,305	1,344	1,400	1,447	1,503
Change (%)		3.31	1.28	0.90	1.54	3.16	4.37	6.44	9.71	6.76	6.84	3.96	0.30	0.80	0.46	0.49	3.04	4.16	3.37	3.81
% of Revenue	27.28	27.19	27.77	27.19	27.29	27.33	26.82	26.40	26.62	26.23	26.28	25.92	25.34	25.14	25.14	25.16	25.01	25.23	25.32	25.06

R&D	172	160	172	185	204	214	216	222	206	215	216	202	211	211	220	230	246	260	253	268
Change (%)		-7.08	7.80	7.74	10.34	4.86	0.53	3.06	-7.10	4.34	0.39	-6.58	4.46	0.01	4.39	4.54	6.91	5.55	-2.46	5.95
% of Revenue	5.86	5.25	5.71	5.97	6.51	6.63	6.26	5.97	5.10	4.91	4.62	4.09	4.17	4.10	4.26	4.44	4.58	4.68	4.43	4.48

OpEx	2,837	2,889	2,867	2,925	2,968	3,048	3,187	3,388	3,669	3,926	4,190	4,376	4,445	4,524	4,505	4,518	4,658	4,809	4,944	5,147
Change (%)		1.81	-0.77	2.03	1.48	2.70	4.54	6.33	8.28	7.00	6.74	4.44	1.58	1.76	-0.40	0.27	3.11	3.23	2.82	4.10
% of Revenue	96.82	95.08	95.16	94.21	94.49	94.23	92.60	91.06	90.62	89.50	89.58	88.75	87.86	88.00	87.24	87.12	86.66	86.65	86.51	85.85

Operating Income	93	150	146	180	173	187	255	333	380	461	487	555	614	617	659	668	717	741	771	848
Change (%)		60.26	-2.47	23.28	-3.65	7.82	36.44	30.55	14.11	21.38	5.77	13.81	10.71	0.45	6.81	1.42	7.34	3.32	4.09	9.99
% of Revenue	3.18	4.92	4.84	5.79	5.51	5.77	7.40	8.94	9.38	10.50	10.42	11.25	12.14	12.00	12.76	12.88	13.34	13.35	13.49	14.15

Interest Expense	-54	-53	-53	-54	-53	-52	-52	-52	-55	-59	-65	-70	-70	-67	-63	-59	-58	-58	-59	-59
Change (%)		-1.74	-0.02	1.61	-1.14	-2.03	-0.87	1.73	4.77	8.35	9.41	8.00	-0.47	-3.98	-5.64	-6.84	-2.42	0.81	1.33	0.06
% of Revenue	-1.83	-1.74	-1.75	-1.73	-1.69	-1.61	-1.50	-1.41	-1.36	-1.36	-1.39	-1.43	-1.38	-1.31	-1.23	-1.14	-1.07	-1.05	-1.03	-0.98

Net Income	582	638	634	293	288	304	368	693	735	799	800	562	585	595	650	689	718	685	710	726
Change (%)		9.55	-0.57	-53.86	-1.48	5.35	21.12	88.37	6.06	8.68	0.12	-29.70	3.93	1.77	9.33	5.96	4.21	-4.65	3.71	2.21
% of Revenue	19.88	21.00	21.06	9.43	9.18	9.39	10.69	18.63	18.16	18.22	17.10	11.41	11.55	11.57	12.59	13.29	13.36	12.34	12.42	12.11

Source: Capital IQ

Synmosa Biopharma Corporation - Income Statement (TTM)

Income Statement (TTM)